2
|
Parra NA, Lu H, Li Q, Stoyanova R, Pollack A, Punnen S, Choi J, Abdalah M, Lopez C, Gage K, Park JY, Kosj Y, Pow-Sang JM, Gillies RJ, Balagurunathan Y. Predicting clinically significant prostate cancer using DCE-MRI habitat descriptors. Oncotarget 2018; 9:37125-37136. [PMID: 30647849 PMCID: PMC6324677 DOI: 10.18632/oncotarget.26437] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2018] [Accepted: 11/16/2018] [Indexed: 12/16/2022] Open
Abstract
Prostate cancer diagnosis and treatment continues to be a major public health challenge. The heterogeneity of the disease is one of the major factors leading to imprecise diagnosis and suboptimal disease management. The improved resolution of functional multi-parametric magnetic resonance imaging (mpMRI) has shown promise to improve detection and characterization of the disease. Regions that subdivide the tumor based on Dynamic Contrast Enhancement (DCE) of mpMRI are referred to as DCE-Habitats in this study. The DCE defined perfusion curve patterns on the identified tumor habitat region are used to assess clinical significance. These perfusion curves were systematically quantified using seven features in association with the patient biopsy outcome and classifier models were built to find the best discriminating characteristics between clinically significant and insignificant prostate lesions defined by Gleason score (GS). Multivariable analysis was performed independently on one institution and validated on the other, using a multi-parametric feature model, based on DCE characteristics and ADC features. The models had an intra institution Area under the Receiver Operating Characteristic (AUC) of 0.82. Trained on Institution I and validated on the cohort from Institution II, the AUC was also 0.82 (sensitivity 0.68, specificity 0.95).
Collapse
Affiliation(s)
- N Andres Parra
- Department of Cancer Physiology, H.L. Moffitt Cancer Center, Tampa, FL, USA
| | - Hong Lu
- Department of Cancer Physiology, H.L. Moffitt Cancer Center, Tampa, FL, USA.,Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
| | - Qian Li
- Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
| | - Radka Stoyanova
- Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Alan Pollack
- Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Sanoj Punnen
- Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Jung Choi
- Department of Radiology, H.L. Moffitt Cancer Center, Tampa, FL, USA
| | - Mahmoud Abdalah
- Department of Cancer Physiology, H.L. Moffitt Cancer Center, Tampa, FL, USA
| | - Christopher Lopez
- Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Kenneth Gage
- Department of Radiology, H.L. Moffitt Cancer Center, Tampa, FL, USA
| | - Jong Y Park
- Department of Cancer Epidemiology, H.L. Moffitt Cancer Center, Tampa, FL, USA
| | - Yamoah Kosj
- Department of Cancer Epidemiology, H.L. Moffitt Cancer Center, Tampa, FL, USA.,Department of Radiation Oncology, H.L. Moffitt Cancer Center, Tampa, FL, USA
| | - Julio M Pow-Sang
- Department of Urology, H.L. Moffitt Cancer Center, Tampa, FL, USA
| | - Robert J Gillies
- Department of Cancer Physiology, H.L. Moffitt Cancer Center, Tampa, FL, USA.,Department of Radiology, H.L. Moffitt Cancer Center, Tampa, FL, USA
| | | |
Collapse
|
5
|
Hoang Dinh A, Melodelima C, Souchon R, Lehaire J, Bratan F, Mège-Lechevallier F, Ruffion A, Crouzet S, Colombel M, Rouvière O. Quantitative Analysis of Prostate Multiparametric MR Images for Detection of Aggressive Prostate Cancer in the Peripheral Zone: A Multiple Imager Study. Radiology 2016; 280:117-27. [PMID: 26859255 DOI: 10.1148/radiol.2016151406] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Purpose To assess the intermanufacturer variability of quantitative models in discriminating cancers with a Gleason score of at least 7 among peripheral zone (PZ) lesions seen at 3-T multiparametric magnetic resonance (MR) imaging. Materials and Methods An institutional review board-approved prospective database of 257 patients who gave written consent and underwent T2-weighted, diffusion-weighted, and dynamic contrast material-enhanced imaging before prostatectomy was retrospectively reviewed. It contained outlined lesions found to be suspicious for malignancy by two independent radiologists and classified as malignant or benign after correlation with prostatectomy whole-mount specimens. One hundred six patients who underwent imaging with 3-T MR systems from two manufacturers were selected (data set A, n = 72; data set B, n = 34). Eleven parameters were calculated in PZ lesions: normalized T2-weighted signal intensity, skewness and kurtosis of T2-weighted signal intensity, T2 value, wash-in rate, washout rate, time to peak (TTP), mean apparent diffusion coefficient (ADC), 10th percentile of the ADC, and skewness and kurtosis of the histogram of the ADC values. Parameters were selected on the basis of their specificity for a sensitivity of 0.95 in diagnosing cancers with a Gleason score of at least 7, and the area under the receiver operating characteristic curve (AUC) for the models was calculated. Results The model of the 10th percentile of the ADC with TTP yielded the highest AUC in both data sets. In data set A, the AUC was 0.90 (95% confidence interval [CI]: 0.85, 0.95) or 0.89 (95% CI: 0.82, 0.94) when it was trained in data set A or B, respectively. In data set B, the AUC was 0.84 (95% CI: 0.74, 0.94) or 0.86 (95% CI: 0.76, 0.95) when it was trained in data set A or B, respectively. No third variable added significantly independent information in any data set. Conclusion The model of the 10th percentile of the ADC with TTP yielded accurate results in discriminating cancers with a Gleason score of at least 7 among PZ lesions at 3 T in data from two manufacturers. (©) RSNA, 2016 Online supplemental material is available for this article.
Collapse
Affiliation(s)
- Au Hoang Dinh
- From INSERM, U1032, LabTau, Lyon, France (A.H.D., R.S., J.L., F.B., S.C., O.R.); CNRS, UMR 5553, BP 53, Grenoble, France (C.M.); Laboratoire d'Ecologie Alpine, Université Joseph Fourier, Grenoble, France (C.M.); Department of Urinary and Vascular Imaging (F.B., O.R.), Department of Pathology (F.M.L.), and Department of Urology (S.C., M.C.), Hospices Civils de Lyon, Hôpital Edouard Herriot, Pavillon P Radio, 5 place d'Arsonval, Lyon 69003, France; Université Lyon 1, Faculté de Médecine Lyon Est, Lyon, France (F.B., S.C., M.C., O.R.); and Department of Urology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France (A.R.)
| | - Christelle Melodelima
- From INSERM, U1032, LabTau, Lyon, France (A.H.D., R.S., J.L., F.B., S.C., O.R.); CNRS, UMR 5553, BP 53, Grenoble, France (C.M.); Laboratoire d'Ecologie Alpine, Université Joseph Fourier, Grenoble, France (C.M.); Department of Urinary and Vascular Imaging (F.B., O.R.), Department of Pathology (F.M.L.), and Department of Urology (S.C., M.C.), Hospices Civils de Lyon, Hôpital Edouard Herriot, Pavillon P Radio, 5 place d'Arsonval, Lyon 69003, France; Université Lyon 1, Faculté de Médecine Lyon Est, Lyon, France (F.B., S.C., M.C., O.R.); and Department of Urology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France (A.R.)
| | - Rémi Souchon
- From INSERM, U1032, LabTau, Lyon, France (A.H.D., R.S., J.L., F.B., S.C., O.R.); CNRS, UMR 5553, BP 53, Grenoble, France (C.M.); Laboratoire d'Ecologie Alpine, Université Joseph Fourier, Grenoble, France (C.M.); Department of Urinary and Vascular Imaging (F.B., O.R.), Department of Pathology (F.M.L.), and Department of Urology (S.C., M.C.), Hospices Civils de Lyon, Hôpital Edouard Herriot, Pavillon P Radio, 5 place d'Arsonval, Lyon 69003, France; Université Lyon 1, Faculté de Médecine Lyon Est, Lyon, France (F.B., S.C., M.C., O.R.); and Department of Urology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France (A.R.)
| | - Jérôme Lehaire
- From INSERM, U1032, LabTau, Lyon, France (A.H.D., R.S., J.L., F.B., S.C., O.R.); CNRS, UMR 5553, BP 53, Grenoble, France (C.M.); Laboratoire d'Ecologie Alpine, Université Joseph Fourier, Grenoble, France (C.M.); Department of Urinary and Vascular Imaging (F.B., O.R.), Department of Pathology (F.M.L.), and Department of Urology (S.C., M.C.), Hospices Civils de Lyon, Hôpital Edouard Herriot, Pavillon P Radio, 5 place d'Arsonval, Lyon 69003, France; Université Lyon 1, Faculté de Médecine Lyon Est, Lyon, France (F.B., S.C., M.C., O.R.); and Department of Urology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France (A.R.)
| | - Flavie Bratan
- From INSERM, U1032, LabTau, Lyon, France (A.H.D., R.S., J.L., F.B., S.C., O.R.); CNRS, UMR 5553, BP 53, Grenoble, France (C.M.); Laboratoire d'Ecologie Alpine, Université Joseph Fourier, Grenoble, France (C.M.); Department of Urinary and Vascular Imaging (F.B., O.R.), Department of Pathology (F.M.L.), and Department of Urology (S.C., M.C.), Hospices Civils de Lyon, Hôpital Edouard Herriot, Pavillon P Radio, 5 place d'Arsonval, Lyon 69003, France; Université Lyon 1, Faculté de Médecine Lyon Est, Lyon, France (F.B., S.C., M.C., O.R.); and Department of Urology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France (A.R.)
| | - Florence Mège-Lechevallier
- From INSERM, U1032, LabTau, Lyon, France (A.H.D., R.S., J.L., F.B., S.C., O.R.); CNRS, UMR 5553, BP 53, Grenoble, France (C.M.); Laboratoire d'Ecologie Alpine, Université Joseph Fourier, Grenoble, France (C.M.); Department of Urinary and Vascular Imaging (F.B., O.R.), Department of Pathology (F.M.L.), and Department of Urology (S.C., M.C.), Hospices Civils de Lyon, Hôpital Edouard Herriot, Pavillon P Radio, 5 place d'Arsonval, Lyon 69003, France; Université Lyon 1, Faculté de Médecine Lyon Est, Lyon, France (F.B., S.C., M.C., O.R.); and Department of Urology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France (A.R.)
| | - Alain Ruffion
- From INSERM, U1032, LabTau, Lyon, France (A.H.D., R.S., J.L., F.B., S.C., O.R.); CNRS, UMR 5553, BP 53, Grenoble, France (C.M.); Laboratoire d'Ecologie Alpine, Université Joseph Fourier, Grenoble, France (C.M.); Department of Urinary and Vascular Imaging (F.B., O.R.), Department of Pathology (F.M.L.), and Department of Urology (S.C., M.C.), Hospices Civils de Lyon, Hôpital Edouard Herriot, Pavillon P Radio, 5 place d'Arsonval, Lyon 69003, France; Université Lyon 1, Faculté de Médecine Lyon Est, Lyon, France (F.B., S.C., M.C., O.R.); and Department of Urology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France (A.R.)
| | - Sébastien Crouzet
- From INSERM, U1032, LabTau, Lyon, France (A.H.D., R.S., J.L., F.B., S.C., O.R.); CNRS, UMR 5553, BP 53, Grenoble, France (C.M.); Laboratoire d'Ecologie Alpine, Université Joseph Fourier, Grenoble, France (C.M.); Department of Urinary and Vascular Imaging (F.B., O.R.), Department of Pathology (F.M.L.), and Department of Urology (S.C., M.C.), Hospices Civils de Lyon, Hôpital Edouard Herriot, Pavillon P Radio, 5 place d'Arsonval, Lyon 69003, France; Université Lyon 1, Faculté de Médecine Lyon Est, Lyon, France (F.B., S.C., M.C., O.R.); and Department of Urology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France (A.R.)
| | - Marc Colombel
- From INSERM, U1032, LabTau, Lyon, France (A.H.D., R.S., J.L., F.B., S.C., O.R.); CNRS, UMR 5553, BP 53, Grenoble, France (C.M.); Laboratoire d'Ecologie Alpine, Université Joseph Fourier, Grenoble, France (C.M.); Department of Urinary and Vascular Imaging (F.B., O.R.), Department of Pathology (F.M.L.), and Department of Urology (S.C., M.C.), Hospices Civils de Lyon, Hôpital Edouard Herriot, Pavillon P Radio, 5 place d'Arsonval, Lyon 69003, France; Université Lyon 1, Faculté de Médecine Lyon Est, Lyon, France (F.B., S.C., M.C., O.R.); and Department of Urology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France (A.R.)
| | - Olivier Rouvière
- From INSERM, U1032, LabTau, Lyon, France (A.H.D., R.S., J.L., F.B., S.C., O.R.); CNRS, UMR 5553, BP 53, Grenoble, France (C.M.); Laboratoire d'Ecologie Alpine, Université Joseph Fourier, Grenoble, France (C.M.); Department of Urinary and Vascular Imaging (F.B., O.R.), Department of Pathology (F.M.L.), and Department of Urology (S.C., M.C.), Hospices Civils de Lyon, Hôpital Edouard Herriot, Pavillon P Radio, 5 place d'Arsonval, Lyon 69003, France; Université Lyon 1, Faculté de Médecine Lyon Est, Lyon, France (F.B., S.C., M.C., O.R.); and Department of Urology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France (A.R.)
| |
Collapse
|